SUMMARY Four hundred and twenty eight patients with endoscopically diagnosed gastric ulcers, randomly allocated to treatment with ranitidine 300 mg at night or ranitidine 150 mg twice daily, were evaluated in a double blind multicentre trial conducted in 10 European countries. After four weeks, complete ulcer healing was observed in 138 of 211 patients (65%) treated with ranitidine 300 mg nocte and in 155 of 217 patients (71%) receiving 150 mg bd. Cumulative healing rates at eight weeks were 90% and 93%, respectively. There was no statistically significant difference between the healing rates at either four or eight weeks. The treatment regimens were equally effective at rapidly reducing the incidence of ulcer related symptoms. Adverse events reported were minor and equally distributed between the two groups. The results of this trial show that 300 mg of ranitidine administered at night is an effective and safe alternative to the current twice daily regimen for the short term treatment of gastric ulcer. 
Controlled clinical trials in a large number of patients with peptic ulcer disease have shown that ranitidine in a dose of 150 mg given twice daily is an effective and safe agent which promotes complete healing of the majority of peptic ulcers within four to eight weeks of treatment.' Ranitidine (Zantac®) was introduced into clinical practice in 1981 and its extensive usage since then has confirmed the safety and efficacy of the drug.
Recent studies have shown that the same total daily dose (300 mg) given at night is an effective and safe alternative to the standard twice daily regimen in the treatment of duodenal ulceration.2 3 In view of the established efficacy of ranitidine 150 mg twice daily in the treatment of gastric ulcer,4 the above findings raise the possibility that a single daily dose of ranitidine may also have a place in the treatment of gastric ulcer. To evaluate this, the present trial compared the use of ranitidine 300 mg at night with ranitidine 150 mg bd in the treatment of gastric ulceration.
with either ranitidine 300 mg Of the 428 patients who were available for analysis at four weeks, 211 received ranitidine 300 mg nocte and 217 received the twice daily There were no statistically significant differences between the healing rates in the two groups at either four (p=0 18) or eight weeks (p=0-31).
There was no evidence that the healing rate at either four or eight weeks was influenced by patient sex, smoking habits or alcohol consumption (Table  3) or that it differed for single or multiple ulcers. Although healing rates varied from country to country, no statistically significant differences were observed at four or eight weeks between the two treatment groups in the individual countries.
ULCER RELATED SYMPTOMS
The degree of severity and incidence of ulcer related symptoms (epigastric pain, heartburn, nausea and vomiting) were found to be similar in the two (1) 9 (3) 7 (2) both treatment regimens and antacid consumption was similar in the two groups. Compliance was good for both treatment regimens.
Clinical trials evaluating the effect of once daily ranitidine (300 mg at night) in the treatment of duodenal ulcer have shown that this regimen is equivalent to the standard 150 mg bd regimen in terms of ulcer healing. These findings have been taken as support for the hypothesis that nocturnal secretion of acid is of particular importance in the pathogenesis of duodenal ulcer. Nocturnal acid secretion in gastic ulcer disease is known to be normal or reduced.9 "' In view of this, the present findings suggest that the equivalence of once and twice a day ranitidine therapy for acute healing of peptic ulcer may result from comparable reductions in 24 hour gastric acidity by the two regimens rather than an effect due to nocturnal administration per se. Whilst studies have compared the effects of 150 mg bd and 300 mg nocte on 24 hour gastric acid secretion in duodenal ulcer and shown them to reduce gastric acidity to a comparable extent, similar studies have yet to be reported for gastric ulcer.
A recent study comparing gastric ulcer healing with ranitidine and omeprazole, an extremely potent inhibitor of gastric acid secretion, 1 reported healing rates of 45, 80 and 90% for ranitidine and 43, 81 and 95% for omeprazole after two, four and eight weeks, respectively, with no statistically significant difference between the two drugs at any time interval. 12 These results indicate that, in contrast with findings in patients with duodenal ulcer,i3 suppression of gastric acidity to a greater extent than that achieved by the present two ranitidine regimens is unlikely to result in more rapid ulcer healing.
The absence of serious or unexpected adverse events in both treatment groups, and the lack of clinically significant biochemical or haematological changes during a treatment for up to eight weeks confirm that ranitidine, whether given in the conventional twice daily regimen or as a single night time dose, is a well tolerated and safe drug for the treatment of acute gastric ulceration. The single night-time dose may improve treatment compliance for certain patients. 
